Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93,104,451
-
Number of holders
-
198
-
Total 13F shares, excl. options
-
75,479,842
-
Shares change
-
+1,607,792
-
Total reported value, excl. options
-
$2,308,615,173
-
Value change
-
+$49,345,949
-
Put/Call ratio
-
66%
-
Number of buys
-
94
-
Number of sells
-
-82
-
Price
-
$30.58
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q2 2021
229 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q2 2021.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 198 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75,479,842 shares
of 93,104,451 outstanding shares and own 81.07% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13,603,670 shares), VANGUARD GROUP INC (8,950,820 shares), EARNEST PARTNERS LLC (6,193,479 shares), STATE STREET CORP (4,089,305 shares), PFM Health Sciences, LP (3,089,152 shares), Camber Capital Management LP (3,000,000 shares), DIMENSIONAL FUND ADVISORS LP (2,768,704 shares), BANK OF AMERICA CORP /DE/ (2,484,454 shares), GLENVIEW CAPITAL MANAGEMENT, LLC (2,476,080 shares), and D. E. Shaw & Co., Inc. (2,242,669 shares).
This table shows the top 198 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.